Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtre
Ajouter des filtres








Gamme d'année
1.
Indian J Cancer ; 2010 Jan-Mar; 47(1): 46-52
Article Dans Anglais | IMSEAR | ID: sea-144293

Résumé

Background : Ephrin A4 is one of the ephrin ligand molecules belonging to the tyrosine kinases receptor family. It was originally identified in a T-lymphoma cell line and seen to be expressed in human adult tissue as well as several tumor types. In our previous study, we showed the unique pattern of ephrin A4 immunohistochemical staining, which differed according to the type of examined bone specimens (normal bone, primary, and metastatic osteosarcoma lesions). The aim of the present study is to evaluate the prognostic impact of ephrin A4 expression in a group of primary osteosarcoma patients. Materials and Methods : Ephrin A4 immunohistochemical expression was carried out on 47 primary osteosarcoma cases. Results : Ephrin A4 was expressed in 82.9% of osteosarcoma cases with cytoplasmic localization in 58.9% of positive cases. The cytoplasmic pattern was significantly associated with aggressive histopathological types of osteosarcoma (P = 0.02), advanced stage (P = 0.04), the presence of metastasis (P = 0.03), inferior response to neoadjuvent chemotherapy (P = 0.04), and tended to be associated with a shorter event-free survival (P = 0.09). Conclusions : The cytoplasmic pattern of ephrin A4 could identify a subgroup of primary osteosarcoma patients with a high liability for progression, poor prognosis, and inferior response to chemotherapy.


Sujets)
Antinéoplasiques/usage thérapeutique , Tumeurs osseuses/métabolisme , Tumeurs osseuses/anatomopathologie , Tumeurs osseuses/thérapie , Éphrine A4/biosynthèse , Humains , Immunohistochimie , Stadification tumorale , Ostéosarcome/métabolisme , Ostéosarcome/anatomopathologie , Ostéosarcome/thérapie , Pronostic , Modèles des risques proportionnels , Résultat thérapeutique , Marqueurs biologiques tumoraux/analyse
2.
J Cancer Res Ther ; 2006 Jan-Mar; 2(1): 20-3
Article Dans Anglais | IMSEAR | ID: sea-111534

Résumé

BACKGROUND: Osteogenic sarcoma (OS) is a highly malignant tumor of the bone. There are few reports in the literature regarding determination of c-erb B-2 (HER-2/neu) expression in cases of OS and also the results are quite variable. AIM: The present study was undertaken to correlate the expression of c-erbB2 with the survival of patients of OS. SETTINGS AND DESIGN: A retrospective study of cases of OS, in which the expression of c-erbB-2 by immunohistochemistry (IHC) was studied and correlated with the survival rate of the patients. MATERIALS AND METHODS: Out of a total of 49 cases, proper follow up data in the form of total and disease free survival was available in only 20 cases. IHC for c-erb-B2 was carried out in these 20 cases. RESULTS: The staining pattern was as follows: no staining in 3 cases, 1 + in 5 cases, 2 + in 3 cases, 3 + in 3 cases and 4 + cytoplasmic positivity in 6 cases. Statistical analysis: Spearman rank correlation test was used to correlate the intensity of cytoplasmic staining of c-erbB-2 with survival rate of the patients, response to chemotherapy and metastasis. CONCLUSIONS: Previous studies have shown that c-erbB-2/HER-2 is an independent prognostic factor in osteogenic sarcoma, but in the present study, its expression was not seen to be correlating with survival rate of the patients. Therefore, further studies are needed to reach a consensus regarding the reliability of c-erbB-2 as an independent prognostic factor in OS.


Sujets)
Adolescent , Adulte , Tumeurs osseuses/métabolisme , Enfant , Femelle , Humains , Immunohistochimie , Mâle , Ostéosarcome/métabolisme , Valeur prédictive des tests , Pronostic , Récepteur ErbB-2/biosynthèse , Études rétrospectives , Analyse de survie
3.
Journal of Huazhong University of Science and Technology (Medical Sciences) ; (6): 445-7, 2005.
Article Dans Anglais | WPRIM | ID: wpr-634256

Résumé

To compare the expression level of metastasis associated-1 (MTA1) gene in high and low metastatic human osteosarcoma cell lines and examine the relationship of MTA1 expression and the metastasis potentiality of osteosarcoma cells, the expression of MTA1 in MG-63 osteosarcoma cell lines with high and low metastasis potential was detected by semiquantitative TR-PCR. Boyden chamber invasion assay was used to evaluate the invasive capacity in vitro in two osteosarcoma cell lines. The low metastasis MG-63 cells were transfected with MTA1 full-length cDNA expression plasmid by lipofectamine and the changes of MTA1 expression and in vitro invasion potential were examined after the transfection. Our results showed that MG63 cell line with high metastasis potential expressed significantly higher MTA1 than that of MG63 cells with low metastasis as reavealed by RT-PCR. The invasion potential of low metastasis MG63 cell line was increased after MTA1 gene transfection. It is concluded that there may be a relationship between MTA 1 and invasive potentiality of human osteosarcoma cells, and the mechanism of MTA1 in osteosarcoma metastasis and its possible role in associated gene therapy deserve further study.


Sujets)
Tumeurs osseuses/métabolisme , Tumeurs osseuses/anatomopathologie , Régulation de l'expression des gènes tumoraux , Histone deacetylases/biosynthèse , Histone deacetylases/génétique , Invasion tumorale , Métastase tumorale , Ostéosarcome/métabolisme , Ostéosarcome/anatomopathologie , ARN messager/biosynthèse , ARN messager/génétique , Protéines de répression/biosynthèse , Protéines de répression/génétique , Cellules cancéreuses en culture
4.
Indian J Pathol Microbiol ; 2004 Oct; 47(4): 528-9
Article Dans Anglais | IMSEAR | ID: sea-75487

Résumé

A rare case of sarcomatoid renal cell carcinoma (RCC) with predominantly osteosarcomatous differentiation occurring in a 36-year-old male is reported. Immunohistochemistry excluded the possibility of primary osteosarcoma of the kidney.


Sujets)
Adulte , Néphrocarcinome/métabolisme , Différenciation cellulaire , Humains , Immunohistochimie , Kératines/métabolisme , Tumeurs du rein/métabolisme , Mâle , Ostéosarcome/métabolisme , Vimentine/métabolisme
SÉLECTION CITATIONS
Détails de la recherche